Clene Announces Q3 2024 Results and ALS Drug Progress
Company Announcements

Clene Announces Q3 2024 Results and ALS Drug Progress

Clene ( (CLNN) ) has issued an update.

Clene Inc., a biopharmaceutical company focused on neurodegenerative diseases, announced its third quarter 2024 financial results, highlighting a meeting with the FDA to discuss accelerated approval for its ALS treatment CNM-Au8. The company raised $7.3 million through stock offerings and amended its debt agreement to extend its financial runway into early 2025. Despite a net loss of $8 million, Clene aims to continue its groundbreaking work in improving neuronal health.

Find detailed analytics on CLNN stock on TipRanks’ Stock Analysis page.

Related Articles
TheFlyClene reports Q3 EPS ($1.22), consensus ($1.32)
Austin AngeloCLNN Upcoming Earnings Report: What to Expect?
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App